Active Biotech (ACTI.ST) Stock Analysis & AI Equity Report
Active Biotech (ACTI.ST) overview
Active Biotech (ACTI.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Active Biotech reported revenue of SEK 0m and operating profit of SEK -37.6m; the year-end share price was 0.05 SEK and market capitalisation was SEK 62.0m. Active Biotech is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Active Biotech's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Active Biotech
Active Biotech AB is a biotechnology company developing pharmaceutical products for cancer and inflammatory eye diseases. Its portfolio includes tasquinimod for hematological malignancies such as myelofibrosis, laquinimod eye drops for non-infectious uveitis, and naptumomab, an antibody-based immunotherapy licensed to NeoTX for solid tumors. The company is based in Lund, Sweden.
Generate the Active Biotech report
Active Biotech is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Active Biotech and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.